Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.91 -1.56 (-5.12%)
Official Closing Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stocks, Gold, Bonds Rally Further, Dollars Tumbles As Traders Anticipate Fed Cuts: What's Driving Markets Friday?
Kicking off the new month, Wall Street continued its strong November momentum, with major U.S. stocks rallying on Friday. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Is Hub Cyber Security (HUBC) Stock Up 30% Today?
Hub Cyber Security stock is rising higher on Friday as HUBC investors react to an expanded partnership with Blackswan Technologies. 
Via InvestorPlace
Why Pfizer Stock Is Sinking Today
The big drugmaker delivered bad news for its top pipeline program. 
Via The Motley Fool
How To Make $500 A Month With Pfizer Stock
Pfizer Inc. (NYSE: PFE) shares closed higher on Wednesday. 
Via Benzinga
How Is The Market Feeling About Pfizer?
Via Benzinga
Is Pfizer Stock a Buy Now?
The company keeps falling out of favor with the market. 
Via The Motley Fool
Uncovering Dividend Opportunities with NYSE:PFE.
Balancing Dividends and Fundamentals: The Case of PFIZER INC (NYSE:PFE). 
Via Chartmill
Why Is Altimmune (ALT) Stock Up 43% Today?
Altimmune stock is rising higher on Friday with heavy trading of ALT shares after posting positive results form a clinical trial. 
Via InvestorPlace
Pfizer Layoffs 2023: What to Know About the Latest PFE Job Cuts
Pfizer layoffs are on the way for workers at the company's Groton, Conn. facility as it seeks to reduce costs by cutting jobs. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Texas Attorney General Alleges Pfizer Misled Public on COVID-19 Vaccine Efficacy
Texas Attorney General Ken Paxton has filed a lawsuit against Pfizer Inc (NYSE: PFE), alleging the pharmaceutical giant misrepresented the efficacy of its widely- 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
Pfizer said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects. PFE stock fell. 
Via Investor's Business Daily
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Pfizer’s Stock Is Down 44% YTD As Woes Continue
Pfizer's shares plunged on Friday after the drugmaker halted the trial of its twice-daily obesity drug. 
Via Talk Markets
Tale Of Two Investigational Obesity Drugs: Altimmune Stock Jumps, While Pfizer Trades Lower
Altimmune Inc (NASDAQ: ALT) announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide  
Via Benzinga
This Twice Daily Weight Loss Drug Has Adverse Side Effects And Pfizer Wants To Discontinue It
Pfizer Inc (NYSE: PFE) reported topline data from the Phase 2b trial investigating its oral weight loss drug Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in... 
Via Benzinga
Texas Sues Pfizer For "Misrepresenting COVID-19 Vaccine Efficacy" And "Conspiring To Censor Public Discourse"
The Texas attorney general is suing pharmaceutical giant Pfizer for misrepresenting the effectiveness of the company's Covid-19 
Via Talk Markets
Topics Lawsuit
Exposures COVID-19 Financial Legal
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion. 
Via Talk Markets
Billionaire Favorites: 3 Ultra-High Yield Stocks the Elite Love
Buying stocks simple for their high dividend yields is risky but these are three stocks the elite love regardless. 
Via InvestorPlace
Loser Stocks: Buy More, Hold Or Sell?
Many investors bought during the exciting go-go days of the pandemic, as stocks surged to new all-time highs. But many stocks, especially the technology growth stocks, plunged in 2022. 
Via Talk Markets
3 Synthetic Biology Stocks Likely to Mint New Millionaires
Synthetic biology stocks are strongly worth considering for several reasons, particularly these three stocks. 
Via InvestorPlace
Companies That Grow Through Acquisitions: Pros And Cons
We hit one of dividend growth investors’ favorite business model types: growth through acquisitions. While it often rhymes with dividend growth, there are pros and cons to consider. 
Via Talk Markets
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent  
Via Benzinga
3 Top-Rated Value Stocks That Analysts Are Loving Now
Stuff your stockings with these top-rated value stocks. Analysts are feeling good about this value stocks heading into 2024. 
Via InvestorPlace
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
Why Biodexa Pharmaceuticals Stock (BDRX) Is Skyrocketing
Biodexa Pharmaceuticals PLC-ADR (NASDAQ: BDRX) shares are trading higher by 60% to $4.48 Monday morning after the company announced it has acquired the rights to tolimidone, an experimental drug... 
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares. 
Via The Motley Fool
These Three Biotech Stocks Are Trading At A Discount
Investors exposed to the biotech sector have seen mixed results this year. 
Via Talk Markets
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued.
The company is working on treatments for breast cancer in a market worth $15 billion, according to the CEO. 
Via Investor's Business Daily
2 Stocks You'll Be Grateful You Bought at These Bargain Prices
These companies are leaders in their industries. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.